Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ahmad, B.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Pharmacology of insulin

Bushra Ahmad

Department of Diabetes, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, OX3 7LJ, UK, bushra.ahmad{at}orh.nhs.uk

Diabetes is associated with microvascular and macrovascular complications leading to significant morbidity and mortality. Glycaemic control is important to prevent and delay the progression of these complications. An ideal insulin regimen in patients with diabetes would mirror the 24-hour insulin profile of a non-diabetic person and thereby prevent hyperglycaemia without inducing hypoglycaemia. This has, until recently, proved difficult to reproduce by regular subcutaneous insulin injections due to the inherent pharmacokinetic properties of the available insulins. Normoglycaemia was rarely achieved without hypoglycaemia compromising the quality of patients' lives. The advent of the new long- and short-acting insulin analogues are expected to both improve glycaemic control leading to a reduction in diabetes-related complications and reduce the incidence of hypoglycaemia thereby offering patients a better lifestyle.

Key Words: insulin • pharmacology • analogues • lispro • aspart • glargine • detemir.

References

  • Heinemann L., Richter B. Clinical Pharmacology of human insulin. Diabetes Care Dec 1993;16(suppl 3):90-100.
  • Chawdhury SA, Dodson EJ, Dodson GG et al. The crystal structures of three non-pancreatic human insulins. Diabetologia 1983;25:460-4.[Web of Science][Medline] [Order article via Infotrieve]
  • Brogden RN, Heel RC Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use. Drugs 1987;34(3):350-71.[Web of Science][Medline] [Order article via Infotrieve]
  • Bolli GB, Di Marchi RD, Park GD, Pramming S., Koivisto VA Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Binder C., Lauritzen T., Faber O., Pramming S. Insulin pharmokinetics. Diabetes Care 1984;7:188-99.[Abstract]
  • Dimitriadis GD, Gerich JE Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983;6:374-7.[Abstract]
  • Brange J., Ribel U., Hansen JF et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988;333:679-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brange J., Owens DR, Kang S., Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990;13:923-54.[Abstract]
  • Brems DN, Alter LA, Beckage MJ et al. Altering the association properties of insulin by amino acid replacement. Protein Eng 1992;5:527-33.[Abstract/Free Full Text]
  • Di Marchi RD, Chance RE, Long HB, Shields JE, Slieker LJ Preparation of an insulin with improved pharmokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor 1. Horm Res 1994;41(suppl 2):S93-S96.
  • Radziuk JM, Davis JC, Pye WS et al. Bioavailability and bioeffectiveness of subcutaneous human insulin and two of it's analogues- LysB28, ProB29-human insulin and AspB10, LysB28, ProB29-human insulin-assessed in a conscious pig model. Diabetes 1997;46:548-56.[Medline] [Order article via Infotrieve]
  • Somwar R., Sweeny G., Ramlal T., Klip A. Stimulation of glucose and amino acid transport and activation of the insulin signalling pathways by insulin lispro in L6 skeletal muscle cells. Clin Ther 1998;20:125-40.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Slieker LJ, Brooke GS, Di Marchi RD et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 1997;40(suppl 2):S54-S61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kurtzhals P., Schaffer L., Sorensen A. et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49(6):999-1005.[Abstract]
  • Glazer NB, Zalani S., Anderson JH Jr, Baastyr EJ 3rd. Safety of insulin lispro: pooled data from clinical trials. Am J Health Syst Pharm 1999;56(6):542-7.[Abstract/Free Full Text]
  • Howey DC, Bowsher RR, Brunelle RL, Woodworth JR [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402.[Abstract]
  • Davey P., Grainger D., MacMillan J., Rajan N., Aristides M., Gliksman M. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis. Clin Ther 1997;19(4):656-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Anderson JH Jr, Brunelle RL, Koivisto VA et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 1997;19: 62-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chase HP, Lockspeiser T., Peery B., Shepherd M., MacKenzie T., Anderson J., Garg SK The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001;24(3):430-4.[Abstract/Free Full Text]
  • Del Sindaco P., Ciofetta M., Lalli C. et al. Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabetic Medicine 1998;15:592-600.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lalli C., Ciofetta M., Del Sindaco P. et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468-77.[Abstract]
  • Stades AM, Hoekstra JB, van den Tweel I., Erkelens DW, Holleman F. Stability Study Group. Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults: real-life design. Diabetes Care 2002;25(4):712-17.[Abstract/Free Full Text]
  • Joseph SE, Korzon-Burakowska A., Woodworth JR et al. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Diabetes Care 1998;21:2098-102.[Abstract]
  • Anderson JH Jr, Brunelle RL, Koivisto VA et al. Reduction in postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment. Diabetes 1997;46:265-70.[Abstract]
  • Gale EA A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med 2000;17(3):209-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Anderson JH Jr, Brunelle RL, Keohane et al. Mealtime treatment with insulin analog improves postprandial hyperglycaemia and hypoglycaemia in patients with non-insulin dependent diabetes mellitus. Arch Int Med 1997;157:1249-55.[Abstract/Free Full Text]
  • Holcombe JH, Zalani S., Arora VK, Mast CJ Lispro in Adolesecents Study Group. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002;24(4):629-38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Heller SR, Ameil SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. UK Lispro Study Group. Diabetes Care 1999;22(10):1607-11.[Abstract/Free Full Text]
  • Brunelle RL, Llewelyn J., Anderson JH, Gale EAM, Koivisto VA Metaanalysis of the Effect of Insulin Lispro on Severe Hypoglycaemia in Patients with Type 1 Diabetes. Diabetes Care 1998;21:1726-31.[Abstract]
  • Launay B., Zinman B., Tildesley HD, Strack T., Chiasson JL Effect of Continuous Subcutaneous Insulin Infusion With Lispro on Hepatic Responsiveness to Glucagon in Type 1 Diabetes. Diabetes Care 1998;21:1627-31.[Abstract]
  • Jacobs MA, Salobir B., Popp-Snijders C., Ader H., Heine RJ Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers. Diabet Med 1997;14(3):248-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Torlone E., Fanelli C., Rambotti AM et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diabetologia 1994;37:713-20.[Web of Science][Medline] [Order article via Infotrieve]
  • McCrimmon RJ, Frier BM Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the analogue lispro human insulin. Diabet Med 1997;14:929-36.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schernthaner G., Wein W., Sandholzer K. et al. Post prandial insulin lispro. A therapeutic option for type 1 diabetic patients. Diabetes Care 1998;21:570-3.[Abstract]
  • Kotsanos JG, Vignati L., Huster W. et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care J 1997;20(6):948-58.
  • Bhattacharyya A., Brown S., Hughes S., Vice PA Insulin Lispro and regular insulin in pregnancy. QJM 2001;94(5):255-60.[Abstract/Free Full Text]
  • Boskovic R., Feig DS, Derewlany L., Knie B., Portnoi G., Koren G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 2003;26(5):1390-4.[Abstract/Free Full Text]
  • Loukovaara S., Immonen I., Teramo KA, Kaaja R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 2002;26(4):1193-8.[CrossRef][Web of Science]
  • Volund A., Brange J., Drejer K. et al. In vitro and in vivo potency of insulin analogues designed for clinical use. Diabet Med 1991;8:839-47.[Web of Science][Medline] [Order article via Infotrieve]
  • Dall V. Preclinical safety pharmacology studies on the rapid-acting insulin analogue insulin aspart. Arzneimittelforschung 1999;49(5):463-70.[Medline] [Order article via Infotrieve]
  • Lindholm A., Jensen LB, Home PD, Raskin P., Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25(5):876-82.[Abstract/Free Full Text]
  • Mudaliar SR, Lindberg FA, Joyce M. et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999;22(9):1501-06.[Abstract/Free Full Text]
  • Kang S., Brange J., Burch A., Volund A., Owens DR Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9, GluB27; AspB10, AspB28) in healthy subjects. Diabetes Care 1991;14:1057-65.[Abstract]
  • Raskin P., Guthrie RA, Leiter L., Riis A., Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23(5):583-8.[Abstract/Free Full Text]
  • Home PD, Lindholm A., Riis A. Insulin aspart vs human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17(11):762-70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Frier BM, Ewing FM, Lindholm A., Hylleberg B., Kanc K. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes. Diabetes Metab Rev 2000;16(4):262-8.[CrossRef][Web of Science]
  • Brunner GA, Hirschberger S., Sendlhofer G. et al. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes. Diabet Med 2000;17(5):371-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Halberg IB, Jacobsen LV, Dahl UL A study on self-mixing insulin aspart with NPH insulin in the syringe before injection. Diabetes 1999;48(suppl 1):A104 (Abstract).
  • Barnett AH A review of basal insulins. Diabet Med 2003;20:873-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Perriello G., De Feo P., Torlone E. et al. The dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 1991;34:21-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49(12):2142-8.[Abstract/Free Full Text]
  • Rosenstock J., Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edward MB Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24(4):631-6.[Abstract/Free Full Text]
  • Pieber TR, Eugene-Jolchine I., Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 Diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000;23(2):157-62.[Abstract]
  • Ciaraldi TP, Carter L., Seipke G., Mudaliar S., Henry RR Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-1. J Clin Endocrinol Metab 2001;86(12):5838-47.[Abstract/Free Full Text]
  • Heinemann L., Sinha K., Weyer C., Loftager M., Hirschberger S., Heise T. Time-action profile of the soluble, fatty acid acylated, long acting insulin analogue NN304. Diabet Med 1999;16(4):332-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vague P., Selam JL, Skeie S. et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycaemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26(3):590-6.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 1, 10-14 (2004)
DOI: 10.1177/14746514040040010201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
C. L Acerini and A. Deeb
Review: New approaches to insulin therapy in children and adolescents with type 1 diabetes
The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 16 - 20.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ahmad, B.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?